Avutometinib Clinical Trials
9 recruitingDrug
Phase 28Phase 13
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Memorial Sloan Kettering Cancer Center20 enrolled8 locationsNCT06394804
Recruiting
Phase 2
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+1 more
Washington University School of Medicine36 enrolled1 locationNCT07126158
Recruiting
Phase 2
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Stage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Adenocarcinoma+1 more
Emory University50 enrolled3 locationsNCT06495125
Recruiting
Phase 2
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Advanced Colorectal Cancer
M.D. Anderson Cancer Center33 enrolled1 locationNCT06369259
Recruiting
Phase 2
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Thyroid Cancer
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT06007924
Recruiting
Phase 1
A Study of Avutometinib for People With Solid Tumor Cancers
Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 1Phase 2
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260
Recruiting
Phase 1Phase 2
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Cutaneous MelanomaBrain Metastases
University of Utah33 enrolled2 locationsNCT06194929
Recruiting
Phase 2
Avutometinib and Defactinib in Diffuse Gastric Cancer
Gastric CancerStomach Cancer
Ryan H. Moy, MD, PhD27 enrolled1 locationNCT06487221